These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6514933)

  • 21. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
    Nomura Y; Komori T; Okuda S; Segawa T
    Arch Int Pharmacodyn Ther; 1979 Jan; 237(1):25-30. PubMed ID: 485682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Permanent haloperidol-induced dopamine receptor up-regulation in the ovariectomized rat.
    Fields JZ; Gordon JH
    Brain Res Bull; 1991 Apr; 26(4):549-52. PubMed ID: 1831063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of chronic lithium on behavioral and biochemical indices of dopamine receptor supersensitivity in the rat.
    Pittman KJ; Jakubovic A; Fibiger HC
    Psychopharmacology (Berl); 1984; 82(4):371-7. PubMed ID: 6427831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN
    Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of drug holidays in an animal model of tardive dyskinesia.
    Bannet J; Belmaker RH; Ebstein RP
    Psychopharmacology (Berl); 1980; 69(2):223-4. PubMed ID: 6779315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal models for tardive dyskinesia: effects of thioridazine.
    Sayers AC; Bürki HR; Ruch W; Asper H
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):291-5. PubMed ID: 616929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
    Schweitzer JW; Schwartz R; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
    Rupniak NM; Kilpatrick G; Hall MD; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1984; 84(4):512-9. PubMed ID: 6441952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experimental tardive dyskinesia.
    Bédard PJ; Boucher R; Larochelle L
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):551-4. PubMed ID: 6891821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of chronic L-dopa administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain.
    Reches A; Wagner HR; Jiang D; Jackson V; Fahn S
    Life Sci; 1982 Jul; 31(1):37-44. PubMed ID: 7109853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia.
    Gattaz WF; Emrich A; Behrens S
    J Neural Transm Gen Sect; 1993; 92(2-3):197-201. PubMed ID: 8369109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haloperidol-induced tardive dyskinesia in monkeys.
    Gunne LM; Bárány S
    Psychopharmacology (Berl); 1976 Nov; 50(3):237-40. PubMed ID: 826968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.
    Globus M; Bannet J; Lerer B; Belmaker RH
    Psychopharmacology (Berl); 1982; 78(1):81-4. PubMed ID: 6815701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estradiol, TRH and striatal dopaminergic mechanisms.
    Bédard PJ; Malouin F; Dipaolo T; Labrie F
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):555-61. PubMed ID: 6819600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tardive dyskinesia: a biological appraoch.
    Barbaccia ML; Trabucchi M
    Prog Clin Biol Res; 1980; 39():181-93. PubMed ID: 6105670
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of intermittent haloperidol treatment on dopamine receptor sensitivity in guinea pigs.
    Koller WC
    Psychopharmacology (Berl); 1984; 84(1):98-100. PubMed ID: 6436898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of lithium on an animal model of tardive dyskinesia.
    Klawans HL; Weiner WJ; Nausieda PA
    Prog Neuropsychopharmacol; 1977; 1(1-2):53-60. PubMed ID: 569341
    [No Abstract]   [Full Text] [Related]  

  • 39. Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
    Rastogi SK; Rastogi RB; Singhal RL; Lapierre YD
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):153-64. PubMed ID: 6137027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.